21 results
Thumbnail

D3.166 - Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children

Thumbnail

D3.168 - Clinical Department of Allergy Center in Linköping

Thumbnail

D3.169 - Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review

Thumbnail

D3.171 - Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma

Thumbnail

D3.173 - Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications

Thumbnail

D3.174 - Short-term tolerance of omlyclo, the omalizumab biosimilar

Thumbnail

D3.175 - Algorithm for Biologics Selection in Severe Asthma

Thumbnail

D3.178 - Assessment of blood rheological properties in children with bronchial asthma

Thumbnail

D3.179 - Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut